The Supplement Industry's Evidence Problem

Most supplement companies build marketing around science. We’d rather build science into marketing.

The dietary supplement industry operates under a regulatory framework — DSHEA — that places the lowest evidentiary bar in consumer health products. No pre-market approval is required. Structure/function claims need no clinical evidence. The FDA can act only after a product is shown to be unsafe, not before.

This framework has created predictable incentives. Cohen (2014) wrote in the New England Journal of Medicine that the supplement industry’s self-regulation has failed, with products frequently containing unlisted ingredients, inaccurate label claims, and doses that bear no relationship to published research. The GAO has issued multiple reports documenting regulatory gaps.

The result: a marketplace where marketing routinely outpaces evidence, and consumers have no easy way to distinguish products built on solid science from those built on speculation, animal studies, or single-study cherry-picking.

How we think about evidence at OptimalAmino

We can’t fix the industry. But we can be explicit about our own standards:

We cite independent, peer-reviewed research. The studies referenced on this site come from institutions and researchers with no financial relationship to OptimalAmino. We believe the evidence for EAAs should stand on its own.

We state what we don’t know. If the evidence is preliminary, we say so. If a claim isn’t supported by human RCTs, we don’t make it. The nucleotide evidence review on this site is a good example — we wrote it because the science doesn’t support the claims being made, and we think you deserve to know that.

We dose at research-supported levels. The EAA doses in our products reflect the amounts shown to maximally stimulate muscle protein synthesis in published studies — not the minimum needed to list the ingredient on the label.

We welcome scrutiny. Every claim on this site is footnoted. Every study is linked. If we’re wrong about something, we want to know — and we’ll update accordingly.

The supplement industry has an evidence problem. We don’t think the solution is more marketing. We think it’s more transparency.

References

1. Cohen PA. Hazards of hindsight — monitoring the safety of nutritional supplements. N Engl J Med. 2014;370(14):1277-1280. PubMed
2. U.S. Government Accountability Office. Dietary supplements: FDA should take further actions to improve oversight and consumer understanding. GAO-09-250. 2009. GAO
3. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167-1170. PubMed